SELLAS Life Sciences Group, Inc.
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $0
- Net income
- -$26.9M
- Total assets
- $78.3M
- Market cap
- $1.6B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Cost of revenue
- $0
- Operating income
- -$28.3M
- Income tax
- $0
- Net income
- -$26.9M
- EPS (basic)
- $-0.25
- EPS (diluted)
- $-0.25
Balance sheet
- Total assets
- $78.3M
- Current assets
- $75.2M
- Total liabilities
- $7.5M
- Current liabilities
- $7.0M
- Shareholders’ equity
- $70.9M
Cash flow
- Operating cash flow
- -$28.4M
- Investing cash flow
- -$57.9M
- Financing cash flow
- $86.3M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
- Market cap
- $1.6B
- EPS (diluted)
- $-0.25
- Dividend yield
- 12.05%
- Shares outstanding
- 202.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 12, 2008
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $26.9M in FY2023.
- Trading 14% below its 52-week high.
- Pays a dividend yielding about 12.05% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SELLAS Life Sciences Group, Inc..
Write a review
News about SELLAS Life Sciences Group, Inc.
News & sentiment via Polygon.io
